Vaccine Pricing: Gavi Fully Self Financing and Accelerated Transition Countries

As of November 2018, nine countries are in a state of accelerated transition from Gavi support to self-financing1, and 16 countries have transitioned out of Gavi support2. These countries have requested WHO to provide more visibility on their vaccine purchase price prospects, for both the proper budgeting of ongoing vaccination programs and the introduction of new vaccines.Three manufacturers – GSK, Merck and Pfizer – have committed to continue providing countries that transition out of Gavi support with access to prices similar to those offered to Gavi-supported countries, or to maintain the prices that these countries are currently paying for certain vaccines, for a certain period of time, depending on commitment terms.

These commitments apply to:

• human papillomavirus vaccine (HPV)

• pneumococcal conjugate vaccine (PCV)

• rotavirus vaccine (Rota